Transitioning Basic Research Into Actual Diagnostics: A Preview

Liza Filshtinsky:
Hello everybody, this is Lisa [Phylstinsky 00:00:02] from the production department at Cambridge Innovation Institute. We're here to tell you about a great talk to take place on August 24th, as part of the eighth Annual Next Generation Diagnostics Summit taking place at the Grand Hyatt in Washington DC. I'm here with a speaker named Tim Minogue who is the chief of the Molecular Diagnostics Department at the United States Army Medical Research Institute for Infectious Diseases. Tim, what speakers and/or topics are you looking forward to hearing at the Molecular Diagnostics for Infectious Disease Conference?

Tim Minogue:
The primary ones that I'm looking forward to seeing are the 2 preceding me. Heike Zistick is presenting on the Draft Guiding for NGS and since we do a lot of NGS network sequencing assets, I'm very much looking forward to seeing what she's going to say about FDA clearance and then Charles Chu gives a decent talk on CLEA and LDT validation of NGS essays that he's working on and from the efforts he as over in [inaudible 00:00:59]. Those are 2 main talks I'm looking forward to seeing. Other topics that the ... Michael Biotta talks the preceding day, that looks very interesting. I have some of the same challenges that we think they have with infectious diseases.

Liza Filshtinsky:
What can people expect to learn and take away from your talk?

Tim Minogue:
My talk is going to center around how the Army and the Defense department is really trying to transition, basically search into actual diagnostics. Some of it will be [section 00:01:24] science, others will be dry, regular story. Hopefully the overall picture will be from a basic research context all the way through to how you get a diagnostic to the FDA.

Liza Filshtinsky:
Who do you believe would benefit the most from attending your talk?

Tim Minogue:
I think the people that are there for the most are people who are interested in Bio defense research and people who are interested in next generation sequencing and what kind of DFS would be required to go forward to FDA.

Liza Filshtinsky:
Tim, it was a pleasure speaking with you today about your upcoming talk from the Molecular Diagnostics for infectious disease track of the next generation diagnostics summit taking place on Wednesday August 24th in Washington DC.